



**CCRIM**

Centre for Commercialization of **Regenerative** Medicine

## **The Centre for Commercialization of Regenerative Medicine (CCRIM): CCRIM announces its inaugural Board of Directors.**

*Powerhouse of regenerative medicine expertise on Board reflects interest in CCRIM's vision.*

September 28, 2011 (Toronto, ON) – The Centre for Commercialization of Regenerative Medicine (CCRIM) is proud to announce its inaugural Board of Directors. The Board represents extensive experience in company creation, international academic excellence and seasoned leaders sourced from the regenerative medicine industry. Chaired by Greg Bonfiglio, Managing Partner of Proteus Venture Partners, the Board is poised to establish CCRIM as an international leader in regenerative medicine commercialization.

Michael May, CEO of CCRIM, is delighted with the caliber of the Board, “We are proud to be working with this accomplished group of regenerative medicine leaders”. May adds, “It is a reflection of the level of interest in the capital-efficient commercialization model offered by CCRIM”.

- Greg Bonfiglio (Chair), Managing Partner of Proteus Venture Partners
- Melissa Carpenter, President, Carpenter Group, Stem Cell Strategies
- Allen Eaves, Founder, President and CEO of Stemcell Technologies Inc.
- Rafi Hofstein, President and CEO of MaRS Innovation
- Peter Lewis, Associate Vice President, Research at the University of Toronto
- Michael May, CEO of Centre for Commercialization of Regenerative Medicine
- Geoff MacKay, President and CEO of Organogenesis
- Ruth McKernan, Senior Vice President of Pfizer Research U.K.
- Stephen Minger, Global Director for Research and Development for Cell Technologies, GE Healthcare, UK
- Lita Nelsen, Director of Technology Licensing Office, Massachusetts Institute of Technology
- Christopher Paige, Vice President, Research, University Health Network
- Duncan Stewart, CEO and Scientific Director, Ottawa Hospital Research Institute
- Peter Zandstra, CSO of Centre for Commercialization of Regenerative Medicine

CCRIM, a Canadian not-for-profit organization, supports the development of technologies that accelerate the commercialization of stem cell- and biomaterials-based technologies and therapies. A network of academics, industry and entrepreneurs, CCRIM translates scientific discoveries into marketable products for patients. CCRIM launched in Toronto's Discovery District on June 14, 2011.

Contact:

Sandra Donaldson,

Manager, Communications

The Centre for Commercialization of Regenerative Medicine

Phone: 416.978.0553 or Cell: 647.926.1228

[sandra.donaldson@ccrm.ca](mailto:sandra.donaldson@ccrm.ca)

[www.ccrm.ca](http://www.ccrm.ca)